Jardiance Seasonal Use Considerations: A Clinical Guide to Year-Round Empagliflozin Management

What Makes Empagliflozin Uniquely Season-Sensitive Among Antidiabetic Drugs

Empagliflozin is an SGLT2 inhibitor that blocks roughly 90% of renal glucose reabsorption in the proximal tubule, causing the kidney to excrete approximately 70 grams of glucose per day in urine. That glucosuria carries an obligate osmotic diuresis, eliminating an estimated 200 to 300 mL of extra fluid per day under baseline conditions. For most patients on a stable diet in a temperate climate, this is well-tolerated.

The problem arises when external conditions amplify fluid losses. Ambient heat, heavy exercise, febrile illness, vomiting, and low carbohydrate intake can each independently stress volume status or shift metabolic fuel use toward ketogenesis. Empagliflozin operates on top of all those stressors simultaneously.

No other commonly prescribed glucose-lowering drug carries this specific combination. Metformin affects lactic acid clearance during hypoxia. Sulfonylureas cause hypoglycemia. But empagliflozin's season-relevant risks are primarily dehydration in summer and euglycemic DKA in winter. Both are preventable with the right protocols.

Why the Osmotic Load Matters More in Heat

The body loses approximately 0.5 to 1.5 L of sweat per hour during moderate exercise in hot conditions. Add the 200 to 300 mL/day obligate glucosuria from empagliflozin and a patient can tip from compensated mild hypovolemia into hemodynamically significant volume depletion faster than expected. Plasma renin and aldosterone both rise within hours of this combined loss, and serum creatinine can climb measurably within 24 to 48 hours.

Why Winter Creates a Different Metabolic Threat

Febrile illness suppresses appetite and often produces vomiting. Both reduce carbohydrate intake dramatically. With glucose scarce, the liver accelerates beta-oxidation and ketone synthesis. Empagliflozin lowers the renal glucose threshold, so plasma glucose stays near-normal even as ketone levels climb into the diagnostic range for DKA (beta-hydroxybutyrate above 3 mmol/L). Blood glucose readings may read 140 to 180 mg/dL, masking a true ketoacidotic state. This is the euglycemic DKA phenotype associated with all SGLT2 inhibitors.

The FDA issued a Drug Safety Communication in 2015 warning specifically about euglycemic DKA with SGLT2 inhibitors, and the prescribing information for empagliflozin carries a bolded warning about this risk (FDA Drug Safety Communication, 2015).

Summer Risks: Heat, Dehydration, and Acute Kidney Injury

High ambient temperatures are the single most common environmental trigger for empagliflozin-related volume depletion. The combination of cutaneous vasodilation, sweat losses, and ongoing glucosuria can reduce effective circulating volume enough to impair renal perfusion.

Dehydration and AKI Risk Profile

Observational data from SGLT2 inhibitor class-wide studies show that acute kidney injury events cluster in the first four to eight weeks of initiation, a period when the volume effect is still being physiologically calibrated. A population-based cohort study by Fralick et al. (BMJ 2020, N=39,879 propensity-matched pairs) found that SGLT2 inhibitor users did not have a significantly higher AKI rate than DPP-4 inhibitor users overall, but subgroup analysis identified higher risk in patients with baseline eGFR <60 mL/min/1.73 m² and those on concurrent ACE inhibitors, ARBs, or diuretics (Fralick et al., BMJ 2020). Summer heat is not isolated as a variable in randomized trials, but the physiological rationale is direct: more fluid loss, same renal perfusion pressure risk.

Patients should be told to drink at minimum 2 L of water per day in summer and to increase that to 2.5 to 3 L on days involving outdoor activity or significant sweating. Plain electrolyte drinks (not high-sugar sports drinks) are appropriate when sweat losses are heavy.

Medication Interactions That Amplify Summer Risk

Concurrent thiazide or loop diuretics sharply increase dehydration risk in hot weather. Patients on hydrochlorothiazide 25 mg plus empagliflozin 10 mg entering a heat wave should have a clear action plan: reduce or hold the diuretic first if symptoms of volume depletion (dizziness, orthostasis, dark urine, decreased urination) appear, and contact their prescriber the same day.

ACE inhibitors and ARBs do not need to be routinely held in summer, but patients and clinicians should recognize that the triple combination of RAAS blockade, SGLT2 inhibition, and heat-related fluid loss creates a physiologically challenging milieu for renal autoregulation. Monitoring serum creatinine and potassium before and during hot months is reasonable clinical practice.

Signs That Warrant Temporary Discontinuation in Summer

Stop empagliflozin and seek evaluation if any of the following appear:

• Orthostatic dizziness or blood pressure drop of more than 20 mmHg systolic on standing
• Urine output drops to <500 mL over 24 hours
• Serum creatinine rises more than 0.3 mg/dL above baseline within 48 hours
• The patient is acutely ill with fever and unable to maintain oral fluid intake

Empagliflozin can generally be restarted once volume status is restored and creatinine returns to baseline.

Winter Risks: Illness, Fasting, and Euglycemic DKA

Euglycemic diabetic ketoacidosis is the most serious seasonal risk associated with empagliflozin. It can develop within 24 to 48 hours of a triggering event and is life-threatening if missed.

Pathophysiology of Euglycemic DKA

SGLT2 inhibition simultaneously lowers glucagon suppression (by reducing glucose-stimulated insulin secretion signaling) and keeps urinary glucose excretion high even as plasma glucose falls. The net metabolic result during carbohydrate restriction is accelerated ketogenesis without the expected hyperglycemia that normally alerts patients and clinicians. Blood glucose may read 120 to 200 mg/dL while arterial pH is below 7.30 and beta-hydroxybutyrate is above 3 mmol/L.

Watts et al. Reviewed 71 published cases of SGLT2 inhibitor-associated euglycemic DKA and found that precipitating factors included reduced oral intake (62% of cases), surgical procedures (23%), and alcohol use (18%) (Watts et al., Diabetes Care 2018). Viral gastroenteritis and influenza, both more prevalent in November through March, map directly onto the "reduced oral intake" category.

The 48-Hour Sick-Day Hold Rule

The 2023 ADA Standards of Medical Care state that SGLT2 inhibitors should be held during acute illness involving vomiting, diarrhea, or significant reduction in oral intake, and that they should not be resumed until the patient has been eating normally for at least 48 hours (ADA Standards of Medical Care in Diabetes 2023).

In practice, this means patients need written sick-day instructions before winter illness season begins, not during an urgent care visit at 2 AM. The instructions should cover:

1. Hold empagliflozin at the first sign of persistent vomiting or inability to eat a normal meal.
2. Check blood glucose every four to six hours.
3. If blood glucose is below 250 mg/dL but the patient feels ill with nausea, abdominal pain, or rapid breathing, go to the emergency department and ask for a ketone check.
4. Do not restart empagliflozin until 48 to 72 hours after normal eating resumes.

Perioperative Management in Winter Elective Surgery Season

Elective surgical procedures cluster in January and February after insurance deductibles reset. The American Society of Anesthesiologists and several endocrinology guidelines recommend holding SGLT2 inhibitors at least three to four days before any procedure requiring general anesthesia or a prolonged NPO period. A joint statement from the Society for Ambulatory Anesthesia (SAMBA 2023) noted that perioperative euglycemic DKA cases with SGLT2 inhibitors had been reported even after minor outpatient procedures, and recommended extending the hold to four days for patients on insulin or who are restricting carbohydrates (SAMBA 2023 Consensus Statement reference via NCBI).

The HealthRX clinical team uses the following seasonal hold framework for empagliflozin:

| Season / Scenario | Action | Resume Criteria | |---|---|---| | Summer: mild dehydration, still eating | Increase fluids; monitor creatinine | Continue if creatinine stable | | Summer: vomiting or AKI (creatinine rise >0.3 mg/dL) | Hold empagliflozin | Resume 48 to 72 h after eating resumes and creatinine at baseline | | Winter: URI without vomiting or fasting | Continue; increase monitoring | No hold required | | Winter: GI illness with vomiting or inability to eat | Hold immediately | Resume 48 to 72 h after normal meals resume | | Pre-surgical (any season) | Hold 3 to 4 days pre-op | Resume after normal eating for 48 to 72 h post-op | | Extended low-carbohydrate diet initiation | Discuss with prescriber; may need hold or dose reduction | Individual assessment |

Exercise, Seasonal Athletic Activity, and Glycemic Dynamics

Many patients with type 2 diabetes increase their physical activity in spring and summer. Empagliflozin changes the metabolic response to exercise in ways that can be beneficial but also need monitoring.

How SGLT2 Inhibition Shifts Exercise Fuel Use

SGLT2 inhibitors modestly lower fasting glucose and shift substrate utilization toward fat oxidation. A crossover study by Yardley et al. (Diabetes Care 2013) found that SGLT2 inhibitors could reduce exercise-related hypoglycemia compared to sulfonylureas, but that the osmotic diuresis continued during exercise, amplifying fluid losses.

Aerobic exercise lasting more than 60 minutes in heat with empagliflozin on board can cause a measurable drop in plasma volume. Patients undertaking marathon training, cycling events, or outdoor manual labor during summer months should:

• Pre-hydrate with 500 mL of water 30 to 60 minutes before activity
• Drink 150 to 250 mL of water or electrolyte solution every 20 minutes during activity
• Weigh themselves before and after exercise (each 1 kg loss approximates 1 L of fluid deficit)

Hypoglycemia Risk During Exercise

Empagliflozin as monotherapy carries very low hypoglycemia risk, because it does not stimulate insulin secretion. The risk rises substantially when it is combined with a sulfonylurea or insulin. Patients on those combinations should reduce their sulfonylurea dose by 25 to 50% if they add a significant new exercise program in spring, and should carry a rapid glucose source.

Urinary and Genital Infections Across Seasons

Glucosuria creates a urine environment favorable to bacterial and fungal growth. Warm, humid months increase this risk through behavioral and microbiological pathways.

Summer Patterns

Warm temperatures accelerate bacterial doubling times in urinary stagnation. Swimwear and tight athletic clothing worn for extended periods in summer create a moist perineal environment that modestly raises candidal vulvovaginitis risk in women. The EMPA-REG OUTCOME trial (N=7,020) reported genital mycotic infections in 6.4% of women on empagliflozin 10 mg vs. 1.8% placebo, and 3.1% of men vs. 0.4% placebo (Zinman et al., NEJM 2015).

Practical Prevention Steps

Patients should be advised to:

• Change out of wet swimwear promptly
• Wear breathable cotton underwear during hot months
• Report any vulvar itching, discharge, or dysuria promptly so antifungal treatment can be started early
• Maintain adequate hydration, which dilutes urine glucose concentration and may reduce bacterial colonization risk

Urinary tract infections in male patients on empagliflozin are less common but include the rare and serious Fournier gangrene (necrotizing fasciitis of the perineum). The FDA added a black box warning for this complication in 2018. Patients with penile or scrotal pain, redness, or swelling should go to the emergency department immediately (FDA 2018 Safety Communication).

Cold and Flu Season: Influenza Vaccination and Empagliflozin Users

Patients with type 2 diabetes are at higher risk for influenza complications. The CDC recommends annual influenza vaccination for all adults with diabetes, with high-dose or adjuvanted formulations preferred for those over 65 (CDC Influenza Recommendations). Empagliflozin has no direct interaction with influenza vaccines, but a febrile post-vaccination reaction (which is common within 24 hours of influenza vaccination) does not generally require holding the drug unless the patient is vomiting or unable to eat.

Patients should be told: a sore arm and mild fever after flu shot does not mean hold Jardiance. But if the flu itself arrives, the sick-day rules above apply immediately.

Cardiovascular Protection Across Seasons: Why Year-Round Adherence Matters

The primary reason to prescribe empagliflozin in patients with type 2 diabetes and established cardiovascular disease is the mortality benefit demonstrated in EMPA-REG OUTCOME. In that randomized trial (N=7,020, median follow-up 3.1 years), empagliflozin reduced the risk of cardiovascular death by 38% (HR 0.62, 95% CI 0.49 to 0.77, P<0.001) compared to placebo, alongside a 35% reduction in hospitalization for heart failure (Zinman et al., NEJM 2015).

Why Seasonal Interruptions Have Real Costs

Seasonal drug holidays, even brief ones of two to four weeks, interrupt the continuous hemodynamic and neurohormonal benefits of SGLT2 inhibition. The cardiorenal protective effects of empagliflozin, including reductions in preload, interstitial fluid accumulation, and uric acid, are not stored. They reverse within days of stopping. Patients and prescribers sometimes rationalize a "break" during illness, but the correct approach is a temporary hold with a defined restart date, not an open-ended discontinuation.

A 2021 analysis of the EMPEROR-Reduced trial (N=3,730) confirmed that empagliflozin reduced the primary composite of CV death or heart failure hospitalization by 25% (HR 0.75, 95% CI 0.65 to 0.86, P<0.001) in patients with HFrEF, including those without diabetes (Packer et al., NEJM 2020). Holding the drug for seasonal reasons without a documented restart plan risks losing this benefit permanently through patient non-resumption.

Blood Pressure and Seasonal Variation

Blood pressure follows a seasonal pattern in most populations, running 3 to 5 mmHg higher in winter months and lower in summer, partly due to cutaneous vasodilation in heat. Empagliflozin reduces systolic blood pressure by approximately 3 to 4 mmHg through its volume-lowering effect. In summer, this may combine with heat-related vasodilation to cause symptomatic hypotension, particularly in elderly patients or those already on three or more antihypertensives. A sitting blood pressure check at the start of summer is reasonable practice for any empagliflozin patient on multiple antihypertensive agents.

Renal Considerations Across the Seasons

The 2022 EMPA-KIDNEY trial (N=6,609) extended empagliflozin's indication to include chronic kidney disease with or without type 2 diabetes, showing a 28% reduction in the primary composite of kidney disease progression or CV death (HR 0.72, 95% CI 0.64 to 0.82, P<0.001) (EMPA-KIDNEY Collaborative Group, NEJM 2023).

Patients with CKD on empagliflozin require closer seasonal monitoring because their reserve for handling volume fluctuations is narrower.

eGFR Monitoring Schedule Across Seasons

For patients with baseline eGFR between 20 and 45 mL/min/1.73 m², checking eGFR at the start of summer and again six to eight weeks into hot weather is clinically justified. A transient eGFR dip of 10 to 15% in the first weeks of summer, if not accompanied by symptoms, is generally not a reason to stop the drug. A sustained drop exceeding 20 to 25% from baseline warrants holding empagliflozin and reassessing concurrent nephrotoxins and volume status.

Patient Communication: Building a Seasonal Safety Checklist

Effective management of seasonal empagliflozin risks depends on patients understanding the plan before the season changes, not during a crisis.

The following checklist framework, reviewed by the HealthRX medical team, covers the minimum information patients should receive at a pre-summer and pre-winter clinic visit:

Pre-Summer (April to May clinic visit):

• Review baseline creatinine and eGFR
• Confirm the patient knows the hydration targets (2 to 3 L water/day in heat)
• Review concurrent diuretic doses; consider reducing if eGFR <45 mL/min
• Confirm the patient has written sick-day instructions
• Discuss genital infection prevention and early reporting

Pre-Winter (October to November clinic visit):

• Confirm influenza vaccination is scheduled or completed
• Review sick-day rules in writing (the 48-to-72-hour hold and restart criteria)
• Ask about any planned elective surgeries; schedule pre-op medication holds
• Discuss ketone testing at home if the patient is at higher DKA risk (type 1 diabetes using off-label SGLT2, very low carbohydrate diet, history of prior DKA)

Point-of-care urine ketone strips cost approximately $10 to $15 for a 50-strip box and are available over the counter. Patients who develop vomiting or malaise during winter illness should check urine ketones before deciding whether to go to the emergency department. A urine ketone reading of 2+ or greater in a symptomatic empagliflozin user warrants same-day emergency evaluation.